Patients treated with anticancer agents often experience a variety of treatment-related skin problems, which can impair their quality of life.
In this cross-sectional study, Dermatology Life Quality Index (DLQI) and clinical information were evaluated in patients under active anticancer treatment using a questionnaire survey and their medical records review.
Of 375 evaluated subjects with anticancer therapy, 136 (36.27%) and 114 (30.40%) were treated for breast cancer and colorectal cancer, respectively. We found that women, breast cancer, targeted agent use, and longer duration of anticancer therapy were associated with higher dermatology-specific quality of life distraction. In addition, itching, dry skin, easy bruising, pigmentation, papulopustules on face, periungual inflammation, nail changes, and palmoplantar lesions were associated with significantly higher DLQI scores. Periungual inflammation and palmoplantar lesions scored the highest DLQI.
We believe our findings can be helpful to clinicians in counseling and managing the patients undergoing anticancer therapy.
Patients with cancer undergoing treatment with anticancer agents often experience various skin problems, such as pruritus, dry skin, facial papulopustules, paronychia, etc. They are at high risk of skin problems, because anticancer agents affect not only cancer cells, but also rapidly proliferating skin cells [
Despite their high prevalence, the skin problems due to anticancer therapy are often neglected because clinicians and healthcare providers are usually more focused on clinical response of tumor itself or potentially life-threatening side effects such as neutropenia. However, adverse skin reactions to these therapies are sometimes so severe that they make significant disturbance to patients and the dose of anticancer agent should be adjusted at times, meaning that they can affect not only the patients’ quality of life (QoL), but also optimal anticancer treatment. Therefore, they must not be ignored and should be evaluated thoroughly by managing physicians.
In this study, we aimed to evaluate the impact of anticancer agents on patients’ QoL. The patients under active anticancer therapy were surveyed using the Dermatologic Life Quality Index (DLQI), a useful dermatology-specific health-related QoL questionnaire. DLQI score was analyzed according to various clinical factors, including demographics, anti-cancer therapy, and specific skin problems induced by anticancer agents.
We conducted a cross-sectional study using a questionnaire survey and their medical records review. Subjects suffering from cancer were recruited from the Seoul National University Cancer Hospital between February 2016 and April 2016. They were adult patients treated actively with anticancer agents at the time of the study; therefore, patients with only past history of anticancer therapy were excluded. Clinical information was obtained from both the review of medical records and questionnaires.
The following clinical information was obtained for each subject from retrospective review of electronic medical records: (1) demographic data (sex, age); (2) type of cancer (cancer of the liver, thyroid, oral cavity, musculoskeletal, central nervous system, biliary ducts, colorectum, head and neck, bladder, kidney, stomach, breast, uterine cervix, prostate gland, pancreas, lung, skin, and hematologic malignancies); (3) type of anticancer agents: targeted agents (trastuzumab, cetuximab, imatinib, bevacizumab, erlotinib, gefitinib, sunitinib, crizotinib, sorafenib, rituximab, pertuzumab, and ramucirumab) and non-targeted chemotherapeutic agents (docetaxel, paclitaxel, cyclophosphamide, adriamycin, vincristine, 5-fluorouracil, cisplatin, oxaliplatin, carboplatin, etoposide, gemcitabine, capecitabine, irinotecan, navelbine, and pemetrexed); (4) the duration of current anticancer therapy; and (5) radiation therapy history.
Using the questionnaire, subjects were asked if they underwent anticancer therapy at the time of the study and if they suffered from the following skin problems: (1) hair loss; (2) itching; (3) dry skin; (4) easy bruising; (5) pigmentation of lips and mucosae; (6) papulopustules on face, scalp, chest, and back; (7) periungual inflammation; (8) nail changes in color or shape; and (9) palmoplantar lesions with redness, exfoliation, and pain. The impact of skin problems on their QoL was evaluated using DLQI (Dermatology Life Quality Index, AY Finlay, GK Khan, April 1992; all rights reserved; License ID of this study: CUQoL1166), which includes questions about how much skin problems affect patients’ QoL during a past week (symptoms like itching, prickling, or pain, shamefulness, disturbances in performing routine tasks, changes in the selection of clothes, impact on social activities or leisure, difficulties in physical, academic or occupational activities, relationship with other people, and sexual life, and distraction they had due to the treatment). A higher DLQI score means a greater impairment of QoL.
IBM SPSS statistics ver. 21.0 (IBM Corp., Armonk, NY) was used for statistical analysis. The differences of DLQI score associated with demographic factors (sex and age), the type of anticancer agents, radiation therapy history, and the type of skin problems were considered statistically significant if the p-values < 0.05 using Student’s t test. Jonckheere-Terpstra test was performed to find a correlation between the duration of anticancer therapy and DLQI scores.
The study protocol was approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 1601-058-734), and written informed consent was obtained from all subjects.
A total of 380 patients visiting Seoul National University Cancer Hospital agreed to participate in this study. We excluded five subjects who were not treated with anticancer therapy at the time of the survey, and 375 subjects with anticancer therapy were finally enrolled, including 155 (41.3%) men and 220 (58.7%) women. The mean age was 56.35 years (range 25 to 84 years). The most patients had breast cancer (136, 36.3%), followed by patients with colorectal cancer (n=114, 30.4%), gastric cancer (n=33, 8.8%), lung cancer (n=21, 5.6%), and hematologic malignancy (n=18, 4.8%). Among them, 267 subjects (71.2%) underwent treatment with non-targeted agents, while other 108 subjects (28.8%) were on at least one targeted agent. We looked up specific types of chemotherapeutic agents used in two major cancer groups. First, among the patients with breast cancer, 71 patients were treated with cyclophosphamide, 65 were treated with doxorubicin, 51 with docetaxel, 24 with trastuzumab, 19 with paclitaxel, 11 with pertuzumab, nine with capecitabine, and eight with gemcitabine (counts are redundant because most of the patients were treated with more than one agent, e.g., combination regimen with doxorubicin and cyclophosphamide) Second, among the patients with colorectal cancer, 82 patients were treated with 5-fluorouracil, 65 with oxaliplatin, 34 with irinotecan, 28 with capecitabine, 27 with bevacizumab, and nine with cetuximab (counts are also redundant due to combination regimen such as ‘FOLFOX’). Three hundred and fifty patients (93.3%) complained at least more than one skin problem. All demographic and clinical variables and subgroup description of patients according to cancer type are summarized in
Mean DLQI score of total study population is 3.74±0.27 (mean±standard error). DLQI scores according to various clinical factors are presented in
We did additional sub-analysis according to the specific questions of DLQI. Among the 10 questions of DLQI, breast cancer patients reported higher scores with statistical significance than the other types of cancer in 9 out of 10 questions. Question number 7 (‘Over the last week, has your skin prevented you from working or studying?’) was the only one with no significant difference between the type of cancer (data not shown).
In a subgroup analysis according to the type of cancer, except for patients with breast cancer, sex differences in QoL were not observed in patients with different types of cancer. In colorectal cancer group, patients aged 60 years or older had more distraction than those aged younger than 60 years. Moreover, patients with a history of radiation therapy in breast cancer groups were found to have more dermatology-related distraction in daily life (
Hair loss was the most frequently reported problem, followed by dry skin and changes in nail color or shape (
Despite the growing interest and attention on anticancer therapy-induced skin problems, their impact on QoL distraction was not much considered. In particular, clinical factors that cause more distraction in dermatology-related QoL have not been studied, although this information can help clinicians to counsel patients and manage their skin problems during anticancer therapy [
In this study, we used DLQI to evaluate the dermatology-related QoL during anticancer therapy. What clinicians see is sometimes in disagreement with what patients actually feel, especially in terms of the impact on QoL [
Several studies reported that older patients with skin disorders presented higher DLQI scores than younger ones [
Instead, women presented higher DLQI than men in this study. It is frequently seen that women report higher rates of morbidity and distraction in many diseases [
However, considering that the subjects with breast cancer presented higher DLQI and that the difference of DLQI between men and women was not found in colorectal and other cancers, the higher DLQI score in women found in this study might be related to the fact that more than half of the women were patients with breast cancer. Although patients with breast cancer were significantly younger than other patients, a subgroup analysis in them suggested that the age was not a causative factor of high DLQI score. Unlike other patients with cancer, patients with breast cancer showed a significant difference in the DLQI score between those with and without radiotherapy history.
Another hypothesis explaining higher DLQI scores in breast cancer group in this study is that the differences in the type of chemotherapeutic agents between cancer groups may have had an effect on the difference in DLQI scores. In breast cancer group, the majority of patients were treated with taxanes (docetaxel, paclitaxel) or anthracyclines (doxorubicin), which was a unique pattern comparing with other cancer groups. They have been well known to induce nail and periungual problems [
Recently, targeted agents, including epidermal growth factor receptor inhibitors became widely used, and some investigators studied their impact on dermatology-specific QoL. Rosen et al. [
In the comparison between the patients with and without a specific skin problem, we found no significant difference between the patients with and without hair loss induced by anticancer therapy. Although hair loss has been well-known to negatively impact the QoL in patients with alopecia areata [
Interestingly, periungual inflammation and palmoplantar lesion were the top two skin problems with the highest DLQI. They are usually accompanied by pain, and limitation of instrumental and self-care daily activities which makes them distinguishable from other problems [
The limitation of this study is that there is a disproportion of clinical characteristics of the study population. Breast cancer and colorectal cancer together affected over 60% of the patients. This may have caused the disproportion of other factors, such as sex and anticancer therapy regimens consequently.
In conclusion, this study showed that women, breast cancer, targeted agent use, and longer duration of anticancer therapy were associated with higher dermatology-specific QoL distraction. All investigated skin problems, except hair loss, significantly impacted dermatology-specific QoL, and periungual inflammation and palmoplantar lesions scored the highest DLQI. Our findings can be helpful to clinicians in counseling and managing the patients undergoing anticancer therapy.
Supplementary materials are available at Cancer Research and Treatment website (
Conflict of interest relevant to this article was not reported.
Comparison of mean DLQI scores in patients between the type of cancer. Data are mean±stdandard error bars using the Independent T-test. Patients with breast cancer have more distraction in their life than those with any other type of cancer. a)Versus colorectal cancer; 5.16 vs. 3.35, p=0.038, b)Versus gastric cancer; 5.16 vs. 2.70, p=0.034, c)Versus others; 5.16 vs. 2.11, p=0.005.
Differences in mean Dermatology Life Quality Index when the patients have a certain specific skin problems or not. *Statistically significant difference.
Clinical characteristics of the study population
Total | Cancer type |
|||
---|---|---|---|---|
Breast cancer | Colorectal cancer | Others | ||
375 | 136 | 114 | 125 | |
Male | 155 (41.3) | 0 | 63 (55.3) | 92 (73.6) |
Female | 220 (58.7) | 136 (100) | 51 (44.7) | 33 (26.4) |
< 60 | 223 (59.5) | 119 (87.5) | 54 (47.4) | 50 (40.0) |
≥ 60 | 152 (40.5) | 17 (12.5) | 60 (52.6) | 75 (60.0) |
Non-targeted agents only | 267 (71.2) | 103 (75.7) | 74 (64.9) | 90 (72.0) |
Any targeted agents | 108 (28.8) | 33 (24.3) | 40 (35.1) | 35 (28.0) |
≤ 12 | 137 (36.5) | 41 (30.2) | 46 (40.4) | 50 (40.0) |
13-24 | 109 (29.1) | 51 (37.5) | 30 (26.3) | 28 (22.4) |
≥ 25 | 129 (34.4) | 44 (32.3) | 38 (33.3) | 47 (37.6) |
Yes | 97 (25.9) | 37 (27.2) | 20 (17.5) | 40 (32.0) |
No | 278 (74.1) | 99 (72.8) | 94 (82.5) | 85 (68.0) |
Hair loss | 283 (75.5) | 125 (91.9) | 77 (67.5) | 81 (64.8) |
Itching | 143 (38.1) | 61 (44.9) | 35 (30.7) | 47 (37.6) |
Dry skin | 230 (61.4) | 99 (72.8) | 66 (57.9) | 65 (52.0) |
Easy bruising | 113 (30.1) | 49 (36.0) | 31 (27.2) | 33 (26.4) |
Pigmentation of lips and oral mucosa | 108 (28.8) | 37 (27.2) | 45 (39.5) | 26 (20.8) |
Papulopustules on face, scalp, or trunk | 89 (23.7) | 40 (29.4) | 21 (18.4) | 28 (22.4) |
Periungual inflammation with pain | 88 (23.5) | 42 (30.9) | 21 (18.4) | 25 (20.0) |
Changes in nail color and shape | 196 (52.3) | 102 (75.0) | 49 (43.0) | 45 (36.0) |
Redness, exfoliation, or pain in palms and soles | 121 (32.3) | 46 (33.8) | 38 (33.3) | 37 (29.6) |
Values are presented as number (%).
Dermatologic Life Quality Index scores according to clinical characteristics
Total |
Cancer type |
|||||||
---|---|---|---|---|---|---|---|---|
Breast cancer |
Colorectal cancer |
Other cancer |
||||||
DLQI | p-value | DLQI | p-value | DLQI | p-value | DLQI | p-value | |
Male | 2.94±0.36 | 0.006 | 3.43±0.54 | 0.840 | 2.61±1.49 | 0.585 | ||
Female | 4.42±0.40 | 5.16±0.54 | 3.25±0.68 | 3.15±0.95 | ||||
< 60 | 4.01±0.37 | 0.374 | 5.13±0.57 | 0.861 | 2.37±0.43 | 0.024 | 3.14±0.77 | 0.470 |
≥ 60 | 3.51±0.42 | 5.41±1.56 | 4.23±0.69 | 2.49±0.52 | ||||
Non-targeted agents only | 3.45±0.33 | 0.046 | 4.72±0.61 | 0.145 | 2.86±0.53 | 0.120 | 2.49±0.49 | 0.335 |
Any targeted agents | 4.69±0.54 | 6.55±1.14 | 4.25±0.70 | 3.43±0.92 | ||||
≤ 12 | 3.01±0.42 | 3.54±0.77 | 2.54±0.61 | 3.02±0.78 | ||||
13-24 | 4.15±0.52 | 4.71±0.75 | 3.67±0.94 | 3.64±1.10 | ||||
≥ 25 | 4.36±0.52 | 0.019 | 7.20±1.17 | 0.010 | 4.08±0.73 | 0.066 | 1.94±0.47 | 0.863 |
Yes | 4.74±0.71 | 0.100 | 7.95±1.36 | 0.011 | 2.50±1.11 | 0.357 | 2.90±0.83 | 0.817 |
No | 3.48±0.28 | 4.12±0.50 | 3.53±0.46 | 2.68±0.51 |
Values are presented as mean±standard error. DLQI, Dermatologic Life Quality Index.
Jonckheere-Terpstra test was performed to find the correlation between the duration of anticancer therapy and DLQI scores. Student’s t-test was performed for other variables.